About Us

Company Overview

SciGen is a rapidly growing biopharmaceutical company that markets and commercializes innovative and affordable healthcare products worldwide. We leverage our commercialization and networking capabilities to in-licenses and distribute branded pharmaceutical products and medical devices to treat endocrinological and oncological diseases, and continuously fill and improve our pipeline and product portfolio. Founded in the Asian Innovation Capital, Singapore in 1988, we currently have operations in Singapore, South Korea, Australia, China, Philippines and present commercially in all 6 continents. With the exceptional commercialization capabilities, regulatory expertise as well as international management experiences, and strategic partnerships built with industry and academic institutes, we strive to deliver hope and make a real and lasting difference to patients and their families.

Commercialization

Outstanding Marketing & Sales team with strong penetration across key emerging markets.

Alliance

Robust alliance management capabilities.

Partnership

Excellent network of regional partners.

Regulatory

Extensive experience in regulatory process.

History Timeline

Preloader

    • 1988

      Founded in Singapore

    • 1992

      SciGen Australia Pty Ltd established

    • 1999

      SciGen Korea Ltd established

    • 2001

      Gensulin®/SciLin® introduced in Europe

    • 2004

      First sales of Gensulin®/SciLin® in Asia

    • 2005

      Business operation in Philippines

    • 2008

      SciTropin A® launched in Korea

    • 2010

      Gensulin®/SciLin® launched in China

    • 2019

      Acquired Zometa® from Novartis

    • 2020

      SciLin® is to receive MA approval in Brazil

    Our Global Presence

    Philippines
    Australia
    China
    Thailand
    Vietnam
    South Korea
    Poland
    Italy